Compare ADMA Biologics Inc (ADMA) vs AFLAC Incorporated (AFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs AFLAC Incorporated — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while AFLAC Incorporated trades at $121.94 (market cap $61.13B). The key difference: AFLAC Incorporated is far larger — about 28× ADMA Biologics Inc's market cap, and AFLAC Incorporated pays a 2% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AFL | |
|---|---|---|
Market Cap | $2.18B | $61.13B |
Sector | Health | Financials |
52-Week High | $20.38 | $129.55 |
52-Week Low | $7.60 | $103.55 |
Enterprise Value | $2.25B | $71.08B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Aflac (AFL) trades at $124.61, down 1.62% with recent earnings misses and bearish technical signals. The stock shows mixed fundamentals with a P/E of 13.44 and net income margin of 26.79%, though revenue declined to $17.36B in 2025. Recent news highlights Japan unit challenges and dividend reliability, with the company maintaining 43 consecutive years of dividend increases.
Outlook remains cautious with analyst consensus at Hold (56.24%) and price target of $117.60 below current levels. Key risks include foreign exchange headwinds and competitive pressures, while the dividend yield and strong cash flow provide support for income-focused investors amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →
